Pfizer reviewing options for consumer healthcare business

The vertical markets two of the ten top selling consumer healthcare brands globally Centrum and Advil.The vertical markets two ten best selling consumer healthcare brands globally Centrum and Advil.

Drug major Pfizer Corporation today stated it’s reviewing various proper options for its consumer healthcare business, including purchase or separation from the vertical.

The organization is going to be thinking about a variety of options together with a full or partial separation from the business via a spin-off, purchase or any other transaction, the business’s Indian arm Pfizer Limited stated inside a regulatory filing.

“Although there’s a powerful link between Consumer Healthcare and aspects of our core biopharmaceutical companies, it’s also distinct enough from your core business that there’s possibility of its value to become more fully realized outdoors the organization,” Pfizer Chairman and Ceo Ian Read stated.

By exploring proper options, the organization can evaluate the best way to fuel the long run success and growth of consumer healthcare while concurrently unlocking potential value for shareholders, he added.

Pfizer consumer healthcare develops, manufactures and markets leading non-prescription medicines, vitamins, and private maintenance systems.

It’s is among the largest OTC healthcare products companies on the planet with 2016 revenues close to $3.4 billion, operating in additional than 90 countries globally.

The vertical markets two ten best selling consumer healthcare brands globally Centrum and Advil.

Additionally, the company has ten brands that every exceeded $100 million in 2016 sales, and many local brands which are top-rated within their particular markets.

Leave a Reply

Your email address will not be published. Required fields are marked *